

Biocon secures 10-Year supply contract for Pertuzumab in Brazil

September 11, 2026 | News

Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer



Indian biopharma firm Biocon has announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country's Productive Development Partnership (PDP) programme.

The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP programme for Pertuzumab.

The PDP provides the consortium exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's demand for Pertuzumab. It also supports the long-term adoption of Biocon's product within Brazil's public oncology network.

Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. As part of the PDP framework, the product will undergo phased localisation in Brazil in the mid to long term.

Shreehas Tambe, CEO & Managing Director, Biocon, said, "Brazil is an important country for Biocon, and our journey here reflects the transformative potential of strong partnerships in building local capabilities and expanding access to high-quality, affordable medicines. This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale. In partnership with Bahiafarma and Bionovis, we are bringing together science, innovation, manufacturing excellence and local expertise to create a more sustainable pathway for access to this important cancer therapy. Together, we are not only supporting better patient outcomes but also helping build a stronger, more resilient healthcare ecosystem in Brazil."

Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Currently, the product is not manufactured locally in Brazil and is a significant expenditure for the country's Unified Health System (SUS).